Show
Sort by
-
- Journal Article
- A1
- open access
Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma : results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
-
A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
-
- Journal Article
- A1
- open access
A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
-
- Conference Paper
- C3
- open access
Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma : a BEACON-Neuroblastoma biomarker study
-
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe : a report from the Innovative Therapies for Children with Cancer (ITCC) consortium
-
Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
-
Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives : current situation, international survey and future perspectives
-
Risk stratification of high-risk metastatic neuroblastoma : a report from the HR-NBL-1/SIOPEN study
-
Accelerating drug development for neuroblastoma - New drug development strategy : an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
-
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance